Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations

Abstract excerpt

Delta-24-based oncolytic viruses are conditional replication adenoviruses developed to selectively infect and replicate in retinoblastoma 1 (Rb)-deficient cancer cells but not normal cell with intact Rb1 pathways. Over the years, there has been a significant evolution in the design of Delta-24 based on a better understanding of the underlying basis for infection, replication, and spread within cancer. One example...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to Viral Infectious Diseases and Gene Expression in Insects
• Share to Virus-based gene therapy research